MICHAEL FRUMOVITZ to Antineoplastic Agents
This is a "connection" page, showing publications MICHAEL FRUMOVITZ has written about Antineoplastic Agents.
Connection Strength
0.255
-
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
Score: 0.144
-
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102.
Score: 0.032
-
Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014 Jun; 16(6):389.
Score: 0.024
-
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
Score: 0.023
-
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report. J Reprod Med. 2009 Apr; 54(4):259-60.
Score: 0.017
-
Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):546-553.
Score: 0.007
-
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug 15; 17(16):5367-78.
Score: 0.005
-
Quality of life and gynecologic malignancies. Curr Oncol Rep. 2005 Nov; 7(6):459-65.
Score: 0.003